Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors - Menzel, Michael; Kirchner, Martina; Kluck, Klaus; Ball, Markus; Beck, Susanne; Allgäuer, Michael; Assmann, Christin; Schnorbach, Johannes; Volckmar, Anna-Lena; Tay, Timothy Kwang Yong; Goldschmid, Hannah; Tan, Daniel SW; et al. (The journal of pathology: clinical research, 2024)
Vorab veröffentlicht: 17. Januar 2024